doi: 10.3389/fmed.2026.1770866 Received 18 December 2025 Revised 09 January 2026 Accepted 19 January 2026 Published 18 February 2026 Volume 13 - 2026 Edited by Anastasios Potiris, National and Kapodistrian University of Athens, Greece Reviewed by Xinghua Yu, Zhejiang University, China Konstantinos Louis, University General Hospital Attikon, Greece Updates Copyright 2026 Jagadesh and Sridharan
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
See our detailed [retatrutide side effects management guide](/guides/retatrutide-side-effects-management-guide) for specific protocols
Growing evidence shows that many people can be considered overweight and healthy, but the relationship between health and weight is complex
PlexusDx patients can use their secure patient portal to report side effects and receive guidance from clinical support staff